$AEON News

AEON Biopharma Q1 EPS $(0.29) Misses $(0.13) Estimate

Reported Friday, AEON Biopharma Receives Additional NYSE American Non-Compliance Notice Over $4M Stockholders' Equity Requirement Amid $55M Stockholders' Deficit

Reported Friday, AEON Biopharma Receives Additional NYSE American Non-Compliance Notice Over $4M Stockholders' Equity Requirement Amid $55M Stockholders' Deficit

AEON Biopharma Q4 EPS $(3.72)

AEON Biopharma Announces Feedback From FDA Following Biosimilar BPD Type 2a Meeting; Co Plans To Request BPD Type 2b Meeting With FDA In 2026 To Discuss Development Of ABP-450 As Biosimilar To BOTOX

AEON Biopharma Names John Bencich As CFO

12 Health Care Stocks Moving In Thursday's Intraday Session

AEON Biopharma Reports BPD Type 2a Meeting With FDA

An Intrinsic Calculation For Aeon Co. (M) Bhd. (KLSE:AEON) Suggests It's 42% Undervalued

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

12 Health Care Stocks Moving In Thursday's Pre-Market Session

AEON Biopharma Announces Execution of Exchange Agreement with Daewoong

AEON Biopharma Executes Agreement With Daewoong Pharmaceutical To Exchange $15M Of Convertible Notes Plus Accrued Interest Into New Equity, $1.5M Of New Notes Due 2030 And Cash-Exercise Warrant For 8M Shares

Investors in Aeon (M) Bhd (KLSE:AEON) have unfortunately lost 24% over the last year

AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling

AEON Biopharma Announces First Closing Of PIPE Resulted In ~$1.79M In Proceeds; Says FDA BPD Type 2a Meeting Now Scheduled For January 21, 2026

AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

AEON Biopharma Q3 EPS $(0.39) Beats $(0.43) Estimate

AEON Biopharma Reports Positive and Robust Biosimilarity Results: Identical Amino Acid Sequence and Highly Similar Functional Analysis Data

AEON Biopharma Announces Two Complementary Transaction Of ~$22M, Eliminating Nearly All Debt